510(k) Report

510(k) · Cleared

Recalled · Class II · 2018

Verigene Enteric Pathogen Nucleic Acid Test (EP)

K142033510(k) TraditionalCleared Oct 10, 201477-day reviewClass II21 CFR 866.3990Recalls 1

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Nanospere,Inc. · PCH Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System

Cleared on Oct 10, 2014 as substantially equivalent to K121894 (Luminex Molecular Diagnostics, Inc., 2013) and 1 other predicate after a 77-day review. Its family tree reaches back 1 generation to 2013. It has been recalled once.

Decided
Oct 10, 2014
Review
77 days
Class
Class II
Product code
PCH
Recalls
1
Predicates
2

Its longest line of descent runs back 1 generation to DEN130003 (2013). 2 ancestors in all. No later device cites it as a predicate yet.

Other ancestors, by year cleared 2013: 1 other ancestorDEN130003 · Xtag Gastrointestinal Pathogen Panel (GPP) Xtag Data Analysis Software for GPP (Tdas) · Luminex Molecular Diagnostics, Inc. · 20132010201220142016
Other ancestors, by generation 1 generation back: 1 other ancestor DEN130003 · Xtag Gastrointestinal Pathogen Panel (GPP) Xtag Data Analysis Software for GPP (Tdas) · Luminex Molecular Diagnostics, Inc. · 20130
  1. Root · 1 generation backDEN130003 Xtag Gastrointestinal Pathogen Panel (GPP) Xtag Data Analysis…Luminex Molecular Diagnostics, Inc. · 2013
  2. This deviceK142033 Verigene Enteric Pathogen Nucleic Acid Test (EP)Nanospere,Inc. · 2014
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1DEN130003Xtag Gastrointestinal Pathogen Panel (GPP) Xtag Data Analysis Software for GPP…Luminex Molecular Diagnostics, Inc.2013—
0 (this device)K142033Verigene Enteric Pathogen Nucleic Acid Test (EP)Nanospere,Inc.2014—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
201310
FIG. 1 — Lineage of K142033, 2013–2014Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PCH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PCH device

  1. #1 K220062 QIAstat-Dx Gastrointestinal Panel 2score 16.7 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K121894Xtag Gastrointestinal Pathogen Panel (GPP) Xtag Data Analysis Software for GPP (Tdas…
Summary page 6
…dicate devices: NSU Instrumentation for clinical multiplex test systems JJH Clinical Sample Concentrator Predicate Devices: xTAG Gastrointestinal Pathogen Panel (GPP) (K121894/K121454) (Luminex Molecular Diagnostics, Inc.) Indications for Use: The Verigene Enteric Pathogens Nucleic Acid Test (EP) is a…
Luminex Molecular Diagnostics, Inc.2013—
*DEN130003Xtag Gastrointestinal Pathogen Panel (GPP) Xtag Data Analysis Software for GPP (Tdas)
Our reading of the summary gave K121454, which is not in FDA’s 510(k) list. The device the summary names is FDA’s De Novo DEN130003, Xtag Gastrointestinal Pathogen Panel (GPP) Xtag Data… (Luminex Molecular Diagnostics, Inc.), granted Jan 14, 2013; older De Novo requests were first filed under a 510(k) number, so this links to the grant.
Luminex Molecular Diagnostics, Inc.2013—

Also cleared against K121894: 3 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
May 8, 2018Class IIZ-2952-2018Under Investigation by firmElevated false positive results Yersinia enterocolitica (Yersinia) from customers using the EP Nucleic Acid Test Cartridges component (20-006-023) from the Verigene EP Nucleic Acid Test Kit (20-005-023).

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • None of the 2 ancestors has a recall.
  • 3 other devices also cite its predicate K121894.

How does its category compare?

All PCH devices

PCH Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.

FDA decisions per year · PCH

7in 2025

2013: 32014: 62015: 22016: 22017: 12018: 42019: 42022: 22023: 12024: 32025: 72026 (partial year): 3
2007high 7 (2025) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PCH

89in 2025

2014: 120 days median2018: 105 days median2019: 191 days median2024: 271 days median2025: 89 days median2026 (partial year): 176 days median
2007high 271 (2024) · low 89 (2025)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PCH

5in 2025

2023: 12025: 5
2007high 5 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · PCH

40in 2025

2014: 12019: 42021: 262022: 472023: 622024: 452025: 40
2007high 62 (2023) · low 0 (2007)2025

MAUDE reports naming product code PCH, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20133—00
2014612001
20152—00
20162—00
20171—00
2018410500
2019419104
20200—00
20210—026
20222—047
20231—162
20243271045
2025789540
202631760—

What is it indicated for?

The Verigene Enteric Pathogens Nucleic Acid Test (EP) is a multiplexed, qualitative test for simultaneous detection and identification of common pathogenic enteric bacteria, viruses and genetic virulence markers from liquid or soft stool preserved in Cary-Blair medium, collected from individuals with signs and symptoms of gastrointestinal infection. The test is performed on the automated Nanosphere Verigene System utilizing reverse transcription (RT)…

Read the full statement (351 words)

The Verigene Enteric Pathogens Nucleic Acid Test (EP) is a multiplexed, qualitative test for simultaneous detection and identification of common pathogenic enteric bacteria, viruses and genetic virulence markers from liquid or soft stool preserved in Cary-Blair medium, collected from individuals with signs and symptoms of gastrointestinal infection. The test is performed on the automated Nanosphere Verigene System utilizing reverse transcription (RT), polymerase chain reaction (PCR), and array hybridization to detect specific gastrointestinal microbial nucleic acid gene sequences associated with the following pathogenic bacteria and viruses:

• Campylobacter Group (composed of C. coli, C. jejuni, and C. lari)

• Salmonella species

• Shigella species (including S. dysenteriae, S. boydii, S. sonnei, and S. flexneri)

• Vibrio Group (composed of V. cholerae and V. parahaemolyticus)

• Yersinia enterocolitica

• Norovirus GI/GII

• Rotavirus A

In addition, EP detects the Shiga toxin 1 gene and Shiga toxin 2 gene virulence markers. Shiga toxin producing E. coli (STEC) typically harbor one or both genes that encode for Shiga Toxins 1 and 2.

EP is indicated as an aid in the diagnosis of specific agents of gastrointestinal illness, in conjunction with other clinical, laboratory, and epidemiological information; however, is not to be used to monitor these infections. EP also aids in the detection and identification of acute gastroenteritis in the context of outbreaks.

Due to the limited number of positive specimens collected for certain organisms during the prospective clinical study, performance characteristics for Yersinia enterocolitica, Vibrio Group and Shigella species were primarily established with contrived specimens.

Concomitant culture is necessary for organism recovery and further typing of bacterial agents.

EP results should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Confirmed positive results do not rule out co-infection with other organisms that are not detected by this test, and may not be the sole or definitive cause of patient illness. Negative EP results in the setting of clinical illness compatible with gastroenteritis may be due to infection by pathogens that are not detected by this test or non-infectious causes such as ulcerative colitis, irritable bowel syndrome, or Crohn’s disease.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K142033: Verigene Enteric Pathogen Nucleic Acid Test (EP).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K142033

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026